Drug intelligence / Profile preview

TEARLINK

Development stage: Unknown
Lead developer: Protech Remedies
Modality: Small Molecules
Administration: Ophthalmic

Overview

TEARLINK is a topical ophthalmic formulation developed by Protech Remedies for the treatment of chronic dry eye disease. Its active ingredient is ciclosporin (0.05% w/v), a small molecule immunosuppressant. The drug works by reducing inflammation in the ocular surface and lacrimal glands, which in turn facilitates increased natural tear production. It is administered as eye drops to provide lubrication and restore ocular health in patients suffering from keratoconjunctivitis sicca.

Brand names: TEARLINKTEARLINK Eye Drops
Other names: ciclosporin 0.05% eye drops

Targets

CN (Calcineurin)

Beyond the preview

Go deeper on TEARLINK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEARLINK.

Explore the full profile